On behalf of the Board, it is with great pleasure that I invite you to consider joining me as a
Shareholder in Azure Health.
The business of Azure Health is the development, production, marketing and sale of health and
wellbeing products, including the development and commercialisation of platforms for the noninvasive delivery of tocotrienols (a form of Vitamin E) for both nutraceutical and pharmaceutical
The Company proposes to generate revenue in the short term by the marketing and sale of
nutraceutical and wellbeing products, and the development of prescription medicine candidates
for Non-Alcoholic Fatty Liver Disease (NAFLD) and pancreatic cancer.
Azure Health is led by a team with significant experience in the healthcare industry. I believe the
Directors and Management of Azure Health have the capabilities to support the development and
growth of Azure Health towards delivering value to the community through its products and services
and to Shareholders.
Azure Health’s vision is to continue the commercialisation of the Invictus delivery platforms (which the
Company acquired in June 2020), strengthen the Company’s research and development
capabilities, and expand and diversify the Company’s product offerings, commencing with the
Invictus nutraceutical products.
Under this Prospectus, Azure Health is offering for subscription up to 15,000,000 shares at an issue price
of $0.20 to raise up to $3,000,000 (before costs and expenses). The Company reserves the right to
accept oversubscriptions of up to 10%. Upon listing on NSX, at the Offer Price, the Company is
expected to have a market capitalisation of approximately $23 million (based on the Minimum
Subscription under the Offer) and $24 million (based on the Maximum Subscription under the Offer).
This Prospectus contains important information in relation to the Offer, including information on Azure
Health and key risks of an investment of this nature. Key risks associated with an investment in the
Company are set out in detail in Section 5.
The purpose of the Offer is to comply with NSX’s requirements for listing the Company on the NSX,
provide funds for the purposes set out in Section 6.3, give the Company access to equity capital
markets for future funding needs, provide a liquid market for Shares in the Company, provide the
Company with the opportunity to benefit from an enhanced profile as a result of being listed and to
enhance the public and financial profile of the Company to facilitate the potential for further growth
of the Company’s business.
While the Company could have remained an unlisted public company while developing its products,
shareholders and potential investors indicated that they saw value from the higher levels of financial
reporting discipline and corporate governance required from a listing. This also makes the Company
better prepared in the event of any corporate activity.
I encourage you to read the Prospectus in full and to carefully consider the Offer, including the risks
of investing in Azure Health. If you have any questions about this Prospectus or how to apply for
Shares, you should seek advice from your accountant, financial adviser, stockbroker, lawyer or other
On behalf of my fellow Directors, I invite you to subscribe for Shares in Azure Health and look forward
to welcoming you as a Shareholder of Azure Health and joining us on what we plan will be a
Azure Health Technology Limited